Lv7
3430 积分 2021-10-11 加入
Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy
11天前
已完结
Chronic lymphocytic leukaemia: from genetics to treatment
11天前
已完结
[China lymphoma diagnosis and treatment guideline (2026 edition)]
11天前
已完结
Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study
13天前
已完结
Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma
13天前
已完结
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia
13天前
已完结
Systematic review of real-world data on the effectiveness and safety profiles of first-line therapies in chronic lymphocytic leukemia
14天前
已完结
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib
14天前
已完结
Insights into the pathogenesis and biology of chronic lymphocytic leukemia through analysis of its B-cell receptor
14天前
已完结
When and How Long to Treat Chronic Lymphocytic Leukemia?
14天前
已关闭
皖公网安备34019202002308
